Riximyo™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

NON-HODGKINS LYMPHOMA (NHL) RIXIMYO® (rituximab) is indicated for treatment of patients with: CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma, CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma, CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy. CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) RIXIMYO® (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia in combination with chemotherapy. RHEUMATOID ARTHRITIS (RA) RIXIMYO® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate. GRANULOMATOSIS WITH POLYANGIITIS (WEGENERS) (GPA) AND MICROSCOPIC POLYANGIITIS(MPA) RIXIMYO® (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with rituximab have not been established.

Source: ARTG

• Shelf lifetime is 3 Years
• Store at 2 to 8 degrees Celsius
• Protect from Light; Do not Freeze; Refrigerate

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, concentrated
• Intravenous Infusion
• clear, colourless to slightly yellowish solution.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 2 vials of 10mL each
• 3 vials of 10mL each

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under the following PBS item codes:

• 13082M (Opens in new tab)
• 13102N (Opens in new tab)
• 13096G (Opens in new tab)
• 13090Y (Opens in new tab)

Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Rituximab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).